Objective  To investigate the causes of deep venous thrombosis (DVT) after fracture in patients with coronary heart disease (CHD) and intervention efficiency of argatroban.

  Methods  A total of 100 patients with CHD were selected as study group, and all of them were diagnosed as DVT after fracture by B type ultrasound examination. Another 100 patients without DVT were selected as control group. The study group was randomly divided into group A and group B, with 50 cases in each group. Group A was treated with urokinase, and group B was treated with urokinase combined with agatroban. Influencing factors of DVT after fracture in patients with CHD were analyzed, and the general data, clinical efficacy, the prothrombin time (PT), activated partial prothrombin time (APTT), D-dimer (D-D) level and platelet count (PLT) before and after treatment were compared between group A and B.

  Results  In the study group, the age of patients was older than the control group, the bed-rest time was longer than the control group, PT and APTT were shorter than the control group, and there were significant differences (P < 0.05). The total effective rate of group B was 94.00%, which was significantly higher than 80.00% of group A (P < 0.05). After treatment, PT and APTT in group A andgroup B were significantly longer than those before treatment, and PT and APTT in group B were significantly longer than group A (P < 0.05). levels of D-D and PLT in group A and group B were significantly lower than those before treatment, and D-D and PLT in group B were significantly lower than group A (P < 0.05).

  Conclusion  The occurrence of DVT after fracture in patients with CHD is related to age, bed-rest time, PT and APTT. Agathorban is effective in the treatment of DVT, which can effectively improve the coagulation state of patients and prevent the occurrence of DVT.